Among these drug candidates, Selonsertib, which was developed by Gilead Sciences and is the first clinical ASK1 inhibitor in the trial treatment of pulmonary arterial hypertension (PAH), diabetic kidney disease (DKD) and nonalcoholic steatohepatitis (NASH). The gene discussed is MAP3K5; the disease is pulmonary arterial hypertension.